Indu A. Muni

Biography

Dr. Muni is currently the CEO of ROMEG Therapeutics, LLC, www.romegrx.com. Dr. Muni founded CutisPharma in 1998 and served as the Company’s CEO until May 2015. Dr. Muni brings over 40 years of experience in the pharmaceutical industry, with a deep background in pharmacy and toxicology. Prior to founding CutisPharma, Dr. Muni served as the CEO of DynaGen, Inc., a publicly-held biotechnology company. Prior to DynaGen, Dr. Muni served in numerous senior level positions in the pharmaceutical, chemical and toxicology testing industries including BioAssay Systems, Inc., Miles Laboratories, and JT Baker. Dr. Muni has a Ph.D. in Biochemistry/Pharmacology from the University of Mississippi. 

Research Interest

CutisPharma Inc., a specialty pharmaceutical company, develops and commercializes proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. The company’s products include oral solutions and suspensions, such as antimicrobials, mouthwashes, and PPIS; suppositories, including progesterone VGS; and topicals, such as hydrocortisone and testosterone. It provides unit-of-use prescription compounding kits for physicians, pharmacists, patients, and managed care providers